ReviewSeminars in nephrology2017
Apolipoprotein L1 Gene Effects on Kidney Transplantation.
Review in Seminars in nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03615235 (APOL1 Long-term Kidney Transplantation Outcomes Network), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Kidney transplantation in obese Black patients: Strategies to improve access and outcomes.World journal of nephrology · 2026Review
- Navigating Genetic Testing in Nephrology: Options and Decision-Making Strategies.Kidney international reports · 2025Review
- A SNARE protective pool antagonizes APOL1 renal toxicity in Drosophila nephrocytes.Cell & bioscience · 2023Article
- The Evolving Role of Diagnostic Genomics in Kidney Transplantation.Kidney international reports · 2022Review
- Improving Access to HLA-Matched Kidney Transplants for African American Patients.Frontiers in immunology · 2022Article
- APOL1 genotyping in kidney transplantation: to do or not to do, that is the question? (pro).Kidney international · 2021Article
- APOL1 at 10 years: progress and next steps.Kidney international · 2021Article
- Variation ofProgress in transplantation (Aliso Viejo, Calif.) · 2020Article
- Apolipoprotein L1 Gene Testing Comes of Age.Kidney360 · 2020Article
- Caveolin-1 rs4730751 single-nucleotide polymorphism may not influence kidney transplant allograft survival.Scientific reports · 2019Observational
- APOL1 Genetic Testing in Living Kidney Transplant Donors.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Review
- The Impact of APOL1 on Chronic Kidney Disease and Hypertension.Advances in chronic kidney disease · 2019Review
- APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.Kidney international · 2018Article
- Apolipoprotein L1 nephropathies: 2017 in review.Current opinion in nephrology and hypertension · 2018Review
- Evaluation of Potential Living Kidney Donors in theJournal of the American Society of Nephrology : JASN · 2018Article
- Xenotransplantation.Organogenesis · 2018Article
- Stakeholder Perspectives on Returning Nonactionable Apolipoprotein L1 (APOL1) Genetic Results to African American Research Participants.Journal of empirical research on human research ethics : JERHREArticle
- The APOL1 gene and kidney transplantation: a review article.Jornal brasileiro de nefrologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The pathogenesis of many common etiologies of nephropathy has been informed by recent molecular genetic breakthroughs. It now is apparent that the ethnic disparity in the risk for nondiabetic chronic kidney disease between African Americans and European Americans is explained largely by variation in the apolipoprotein L1 gene (APOL1). The presence of two APOL1 renal risk variants markedly increases an individual's risk for kidney disease. In transplantation, kidneys from deceased African Americans with two APOL1 renal risk variants have shorter survival intervals after engraftment, regardless of the ethnicity of the recipient. Precision medicine will transform the clinical practice of nephrology and kidney transplantation, and play an important role in the allocation of kidneys from deceased and living kidney donors with recent African ancestry. This article reviews existing data on APOL1 in deceased-donor and living-donor kidney transplantation. It considers the impact of including APOL1 genotyping in decisions on the allocation and discard of deceased-donor kidneys, as well as the selection of living donors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.